Recombinant Mycobacterium bovis BCG

被引：75

作者：

Bastos, Reginaldo G. ^{[2
]}

Borsuk, Sibele ^{[1
]}

Seixas, Fabiana K. ^{[1
]}

Dellagostin, Odir A. ^{[1
]}

机构：

[1] Univ Fed Pelotas, Ctr Biotecnol, Mol Biol Lab, BR-96010900 Pelotas, RS, Brazil

[2] Washington State Univ, Dept Vet Microbiol & Pathol, Pullman, WA 99164 USA

来源：

VACCINE | 2009年 / 27卷 / 47期

关键词：

Mycobacterium bovis BCG; Recombinant BCG; Heterologous expression; Immunomodulator; BACILLUS-CALMETTE-GUERIN; HUMAN-IMMUNODEFICIENCY-VIRUS; SURFACE PROTEIN-A; CELLULAR IMMUNE-RESPONSES; EXPRESSING INTERFERON-GAMMA; RESPIRATORY-SYNDROME-VIRUS; GLUTATHIONE-S-TRANSFERASE; CYTOTOXIC T-LYMPHOCYTES; LYME-DISEASE VACCINE; PROTECTIVE IMMUNITY;

D O I：

10.1016/j.vaccine.2009.08.044

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The Bacillus Calmette-Guerin (BCG) is an attenuated strain of Mycobacterium bovis that has been broadly used as a vaccine against human tuberculosis. This live bacterial vaccine is able to establish a persistent infection and induces both cellular and humoral immune responses. The development of mycobacterial genetic systems to express foreign antigens and the adjuvanticity of BCG are the basis of the potential use of this attenuated mycobacterium as a recombinant vaccine. Over the years, a range of strategies has been developed to allow controlled and stable expression of viral, bacterial and parasite antigens in BCG. Herein, we review the strategies developed to express heterologous antigens in BCG and the immune response elicited by recombinant BCG constructs. In addition, the use of recombinant BCG as an immunomodulator and future perspectives of BCG as a recombinant vaccine vector are discussed. (C) 2009 Elsevier Ltd. All rights reserved.

引用

页码：6495 / 6503

页数：9

共 126 条

[1] Humoral and cellular immune responses in mice immunized with recombinant Mycobacterium bovis bacillus Calmette-Guerin producing a pertussis toxin-tetanus toxin hybrid protein [J].

Abomoelak, B ;

Huygen, K ;

Kremer, L ;

Turneer, M ;

Locht, C .

INFECTION AND IMMUNITY, 1999, 67 (10) :5100-5105

[2] A novel TB vaccine; towards a strategy based on our understanding of BCG failure [J].

Agger, EM ;

Andersen, P .

VACCINE, 2002, 21 (1-2) :7-14

[3] HUMORAL AND CELL-MEDIATED IMMUNE-RESPONSES TO LIVE RECOMBINANT BCG-HIV VACCINES [J].

ALDOVINI, A ;

YOUNG, RA .

NATURE, 1991, 351 (6326) :479-482

[4] BCG immunotherapy of bladder cancer: 20 years on [J].

Alexandroff, AB ;

Jackson, AM ;

O'Donnell, MA ;

James, K .

LANCET, 1999, 353 (9165) :1689-1694

[5] Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guerin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity [J].

Ami, Y ;

Izumi, Y ;

Matsuo, K ;

Someya, K ;

Kanekiyo, M ;

Horibata, S ;

Yoshino, N ;

Sakai, K ;

Shinohara, K ;

Matsumoto, S ;

Yamada, T ;

Yamazaki, S ;

Yamamoto, N ;

Honda, M .

JOURNAL OF VIROLOGY, 2005, 79 (20) :12871-12879

[6] Immunotherapy of experimental bladder cancer with recombinant BCG expressing interferon-γ [J].

Arnold, J ;

de Boer, EC ;

O'Donnell, MA ;

Böhle, A ;

Brandau, S .

JOURNAL OF IMMUNOTHERAPY, 2004, 27 (02) :116-123

[7] Protection against tuberculosis induced by oral prime with Mycobacterium bovis BCG and intranasal subunit boost based on the vaccine candidate Ag85B-ESAT-6 does not correlate with circulating IFN-γ producing T-cells [J].

Badell, Edgar ;

Nicolle, Fabienne ;

Clark, Simon ;

Majlessi, Laleh ;

Boudou, Frederic ;

Martino, Angelo ;

Castello-Branco, Luiz ;

Leclerc, Claude ;

Lewis, David J. M. ;

Marsh, Philip D. ;

Gicquel, Brigitte ;

Winter, Nathalie .

VACCINE, 2009, 27 (01) :28-37

[8]

Bai Jia-ning, 2007, Weishengwu Xuebao, V47, P324

[9] Virulence, immunogenicity, and protective efficacy of two recombinant Mycobacterium bovis bacillus calmette-gue'rin strains expressing the antigen ESAT-6 from Mycobacterium tuberculosis [J].

Bao, L ;

Chen, W ;

Zhang, HD ;

Wang, XY .

INFECTION AND IMMUNITY, 2003, 71 (04) :1656-1661

[10] RECOMBINANT BCG AS A CANDIDATE ORAL VACCINE VECTOR [J].

BARLETTA, RG ;

SNAPPER, B ;

CIRILLO, JD ;

CONNELL, ND ;

KIM, DD ;

JACOBS, WR ;

BLOOM, BR .

RESEARCH IN MICROBIOLOGY, 1990, 141 (7-8) :931-939

← 1 2 3 4 5 6 7 8 9 10 →